MCID: RBS001
MIFTS: 54

Rabies

Categories: Rare diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Rabies

MalaCards integrated aliases for Rabies:

Name: Rabies 12 50 56 52 41 3 42 14 69
Lyssa 12 50

Characteristics:

Orphanet epidemiological data:

56
rabies
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),<1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



Summaries for Rabies

MedlinePlus : 41 rabies is a deadly animal disease caused by a virus. it can happen in wild animals, including raccoons, skunks, bats and foxes, or in dogs, cats or farm animals. people get it from the bite of an infected animal. in people, symptoms of rabies include fever, headache and fatigue, then confusion, hallucinations and paralysis. once the symptoms begin, the disease is usually fatal. a series of shots can prevent rabies in people exposed to the virus. you need to get them right away. if an animal bites you, wash the wound well; then get medical care. to help prevent rabies vaccinate your pet. rabies vaccines are available for dogs, cats and farm animals don't let pets roam don't approach stray animals. animals with rabies might be aggressive and vicious, or tired and weak centers for disease control and prevention

MalaCards based summary : Rabies, also known as lyssa, is related to erythema multiforme and spoan syndrome, and has symptoms including diarrhea, migraine and seizures. An important gene associated with Rabies is PML (Promyelocytic Leukemia), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Atovaquone and chloroquine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and spinal cord, and related phenotype is immune system.

Disease Ontology : 12 A viral infectious disease that results_in inflammation located in brain or located in spinal cord, has material basis in Rabies virus, which is transmitted_by bite of an infected animal, or transmitted_by contact of mucous membranes with saliva of an infected animal. The infection has symptom fever, has symptom headache, has symptom prickling or itching sensation at the site of bite, has symptom anxiety, has symptom confusion, has symptom agitation, has symptom delirium, has symptom difficulty swallowing, has symptom hydrophobia, and has symptom paralysis.

CDC : 3 Rabies is a preventable viral disease of mammals most often transmitted through the bite of a rabid animal. The vast majority of rabies cases reported to the Centers for Disease Control and Prevention (CDC) each year occur in wild animals like raccoons, skunks, bats, and foxes.

Wikipedia : 72 Rabies is a viral disease that causes inflammation of the brain in humans and other mammals. Early... more...

Related Diseases for Rabies

Diseases related to Rabies via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 102)
id Related Disease Score Top Affiliating Genes
1 erythema multiforme 29.6 ALB CXCL10 TLR3
2 spoan syndrome 10.5 CD40LG STAT1
3 middle ear carcinoma 10.5 ALB CD40LG
4 microinvasive cervical squamous cell carcinoma 10.5 ALB CD40LG
5 aniseikonia 10.5 CD40LG NCAM1
6 cutaneous ganglioneuroma 10.5 CD40LG NCAM1
7 estrogen excess 10.4 ALB CD40LG
8 fragile x syndrome type 2 10.4 ALB CD40LG
9 cd40 ligand deficiency 10.4 CD40LG STAT1
10 gonococcal synovitis 10.4 CD40LG STAT1
11 nuchal bleb, familial 10.4 CD40LG IGHM
12 spastic paraplegia 15, autosomal recessive 10.4 MX1 STAT1 STAT2
13 scrotum basal cell carcinoma 10.3 CD40LG MX1
14 adie pupil 10.3 ALB CD40LG
15 left bundle branch hemiblock 10.3 CD40LG STAT1 STAT2
16 diabetes mellitus, insulin-dependent, 22 10.3 IRF3 MX1 TLR3
17 immune-complex glomerulonephritis 10.3 ALB CD40LG
18 yellow fever 10.2 ALB NGFR
19 cutaneous fibrous histiocytoma 10.2 ALB CD40LG TLR3
20 motion sickness 10.2 ALB CD40LG NGFR
21 epidermolysis bullosa acquisita 10.2 ALB CCL5 STAT1
22 indian tick typhus 10.2 CCL5 CD40LG
23 vaginal mullerian papilloma 10.2 CD40LG MX1
24 chronic inflammatory demyelinating polyneuritis 10.2 ALB CD40LG
25 encephalitis 10.1
26 neuronitis 10.1
27 spinocerebellar ataxia, autosomal recessive 21 10.1 NCAM1 PML STAT1
28 upper lip cancer 10.0 CD40LG STAT1 STAT2 TLR3
29 temporal arteritis 10.0 CD40LG MX1
30 rocky mountain spotted fever 10.0 CD40LG CXCL10
31 late yaws 10.0 ALB CCL5 CD40LG
32 fanconi syndrome 10.0 CCL5 CXCL10
33 acute chest syndrome 9.9 ALB CCL5 CD40LG
34 dyskeratosis congenita 9.9 ALB CD40LG CXCL10
35 malignant eyelid melanoma 9.9 CD40LG CXCL10
36 opportunistic bacterial infectious disease 9.8 ALB CD40LG CXCL10
37 viral encephalitis 9.8
38 eczematous dermatitis of eyelid 9.8 CXCL10 IRF3 STAT1 TLR3
39 adrenal gland disease 9.8 ALB CD40LG
40 dentinogenesis imperfecta 9.8 ALB CD40LG STAT1 STAT2 TLR3
41 vaccinia 9.8
42 tetanus 9.8
43 transmitted_by 9.8
44 ovarian mucinous adenofibroma 9.7 CCL5 CXCL10 MX1
45 acute disseminated encephalomyelitis 9.7
46 transverse myelitis 9.7
47 serotonin syndrome 9.7
48 psychotic disorder 9.7
49 newcastle disease 9.7
50 myelitis 9.7

Graphical network of the top 20 diseases related to Rabies:



Diseases related to Rabies

Symptoms & Phenotypes for Rabies

Human phenotypes related to Rabies:

56 32 (show all 19)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 diarrhea 56 32 hallmark (90%) Very frequent (99-80%) HP:0002014
2 migraine 56 32 hallmark (90%) Very frequent (99-80%) HP:0002076
3 seizures 56 32 occasional (7.5%) Occasional (29-5%) HP:0001250
4 depression 56 32 hallmark (90%) Very frequent (99-80%) HP:0000716
5 hallucinations 56 32 hallmark (90%) Very frequent (99-80%) HP:0000738
6 fever 56 32 hallmark (90%) Very frequent (99-80%) HP:0001945
7 sudden cardiac death 56 32 occasional (7.5%) Occasional (29-5%) HP:0001645
8 insomnia 56 32 hallmark (90%) Very frequent (99-80%) HP:0100785
9 vocal cord paresis 56 32 hallmark (90%) Very frequent (99-80%) HP:0001604
10 anxiety 56 32 hallmark (90%) Very frequent (99-80%) HP:0000739
11 cerebral palsy 56 32 frequent (33%) Frequent (79-30%) HP:0100021
12 anorexia 56 32 hallmark (90%) Very frequent (99-80%) HP:0002039
13 paresthesia 56 32 hallmark (90%) Very frequent (99-80%) HP:0003401
14 attention deficit hyperactivity disorder 56 32 hallmark (90%) Very frequent (99-80%) HP:0007018
15 excessive salivation 56 32 hallmark (90%) Very frequent (99-80%) HP:0003781
16 nausea and vomiting 56 32 hallmark (90%) Very frequent (99-80%) HP:0002017
17 reduced consciousness/confusion 56 32 occasional (7.5%) Occasional (29-5%) HP:0004372
18 recurrent pharyngitis 56 32 hallmark (90%) Very frequent (99-80%) HP:0100776
19 behavioral abnormality 56 Very frequent (99-80%)

UMLS symptoms related to Rabies:


fever, pruritus

MGI Mouse Phenotypes related to Rabies:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.32 CCL5 CD40LG CXCL10 IKBKE IRF3 NGFR

Drugs & Therapeutics for Rabies

Drugs for Rabies (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atovaquone Approved Phase 4 95233-18-4 74989
2
chloroquine Approved, Vet_approved Phase 4 54-05-7 2719
3
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
4
Proguanil Approved Phase 4 500-92-5 4923
5 Antibodies Phase 4,Phase 2,Phase 3,Phase 1
6 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
7 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
8 gamma-Globulins Phase 4,Phase 2,Phase 3,Phase 1
9 Immunoglobulins, Intravenous Phase 4,Phase 2,Phase 3,Phase 1
10 Rho(D) Immune Globulin Phase 4,Phase 2,Phase 3,Phase 1
11 Antibodies, Blocking Phase 4,Phase 2
12 Anti-Bacterial Agents Phase 4,Phase 1
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Antimetabolites Phase 4,Phase 2
15 Antirheumatic Agents Phase 4,Phase 2
16 Analgesics Phase 4
17 Analgesics, Non-Narcotic Phase 4
18 Anthelmintics Phase 4
19 Anti-Inflammatory Agents Phase 4
20 Anti-Inflammatory Agents, Non-Steroidal Phase 4
21 Antimalarials Phase 4,Phase 3
22 Antiparasitic Agents Phase 4,Phase 3
23 Antiprotozoal Agents Phase 4,Phase 3
24 Atovaquone, proguanil drug combination Phase 4
25 Chloroquine diphosphate Phase 4 50-63-5
26 Peripheral Nervous System Agents Phase 4
27
Amodiaquine Approved Phase 3 86-42-0 2165
28
Pyrimethamine Approved, Vet_approved Phase 3 58-14-0 4993
29
Sulfadoxine Approved Phase 3 2447-57-6 17134
30
Lactitol Investigational Phase 3 585-86-4 3871
31 Cathartics Phase 3
32 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
33 Laxatives Phase 3
34 Renal Agents Phase 3
35
Aluminum hydroxide Approved Phase 2,Phase 1 21645-51-2
36
Abacavir Approved, Investigational Phase 2 136470-78-5 65140 441300
37
Efavirenz Approved, Investigational Phase 2 154598-52-4 64139
38
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
39
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
40
Zidovudine Approved Phase 2 30516-87-1 35370
41 Antibodies, Monoclonal Phase 2
42
QS 21 Phase 2,Phase 1 141256-04-4
43 Adjuvants, Immunologic Phase 2,Phase 1
44 Antacids Phase 2,Phase 1
45 Anti-Ulcer Agents Phase 2,Phase 1
46 Antifungal Agents Phase 2
47 Anti-HIV Agents Phase 2
48 Anti-Retroviral Agents Phase 2
49 Antiviral Agents Phase 2,Phase 1
50 Calcineurin Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 101)

id Name Status NCT ID Phase Drugs
1 Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose Unknown status NCT01173302 Phase 4
2 Diagnostic Immunization With Rabies Vaccine in Patients With PID Unknown status NCT02490956 Phase 4
3 Rabies Immune Plasma Booster Study Completed NCT01063140 Phase 4
4 The Protection Effect of Speeda® Rabies Vaccine for Human Use Completed NCT01827917 Phase 4
5 Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules Completed NCT01365494 Phase 4
6 Immunogenicity and Safety of Verorab™ in Indian Population Completed NCT00260351 Phase 4
7 Immunogenicity of Rabies Vaccine for Pre Exposure Completed NCT02374814 Phase 4 Rabies vaccine;Placebo
8 A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children Completed NCT02991872 Phase 4
9 The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use Completed NCT01821911 Phase 4
10 Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. Recruiting NCT02564471 Phase 4 Chloroquine;Atovaquone and Proguanil;Doxycycline
11 Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG Recruiting NCT01137045 Phase 4
12 A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children Not yet recruiting NCT03192371 Phase 4
13 Phase II/III Study of the Safety and Effectiveness of HRIG With Co-administration of Active Rabies Vaccine in Healthy Subjects Unknown status NCT02040090 Phase 2, Phase 3 Active rabies vaccine (US-FDA approved)
14 Early Rabies Vaccine Immunization in Primary School Children Completed NCT01107275 Phase 3
15 Simplifying the Rabies Pre-exposure Vaccination Completed NCT01388985 Phase 3
16 Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine Completed NCT01339312 Phase 3
17 Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age Completed NCT02177032 Phase 3
18 A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects Completed NCT02491541 Phase 3
19 Purified Rabies Vaccine for Human Use (Chick-embryo Cell) Completed NCT00345319 Phase 3
20 Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects Completed NCT01662440 Phase 3
21 A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults Completed NCT01680016 Phase 3
22 Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule) Completed NCT00825305 Phase 3
23 Safety and Immunogenicity of Freeze-dried Rabies Vaccine(MRC-5 Cell) in Chinese Humans Completed NCT02288286 Phase 3
24 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed NCT01466387 Phase 3
25 Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children Completed NCT01148459 Phase 3
26 Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa Completed NCT00866619 Phase 3
27 Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Recruiting NCT03143218 Phase 3 SMC with SP+AQ;SMC placebo
28 A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis. Active, not recruiting NCT02545517 Phase 3
29 Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen Active, not recruiting NCT01622062 Phase 3
30 An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial Active, not recruiting NCT00872963 Phase 2, Phase 3
31 Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies Not yet recruiting NCT02912845 Phase 3 KamRAB - HRIG
32 Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects Not yet recruiting NCT03264157 Phase 2, Phase 3 HRIG
33 Single Center, Open Label, Follow up Study in Subjects Who Previously Received Rabies Vaccine as Simulated Post-Exposure Regimen Terminated NCT01067079 Phase 3
34 One-visit Multi-site Intradermal Rabies Vaccination - Dose Finding Unknown status NCT02276625 Phase 2
35 Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine Unknown status NCT00652275 Phase 2
36 Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen Completed NCT01877395 Phase 2
37 Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen Completed NCT01930357 Phase 2
38 Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use Completed NCT01784874 Phase 2
39 Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen Completed NCT02956421 Phase 2
40 Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults Completed NCT00948272 Phase 2
41 Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults Completed NCT01228383 Phase 2
42 Rabies Immunization Concomitant With JEV in Children Completed NCT00703521 Phase 2
43 A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects Completed NCT00656097 Phase 2
44 Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents Completed NCT00708084 Phase 2
45 Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers Completed NCT00694460 Phase 2
46 Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects. Completed NCT02559921 Phase 2
47 Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali Completed NCT00460525 Phase 2
48 Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine Completed NCT00223990 Phase 2
49 Efficacy of Malaria Vaccines in Kenyan Adults Completed NCT01666925 Phase 2
50 Efficacy of Candidate Malaria Vaccines in Senegalese Adults Completed NCT01658696 Phase 2

Search NIH Clinical Center for Rabies

Cochrane evidence based reviews: rabies

Genetic Tests for Rabies

Anatomical Context for Rabies

MalaCards organs/tissues related to Rabies:

39
Brain, Testes, Spinal Cord, Liver, Bone, Bone Marrow, Skin

Publications for Rabies

Articles related to Rabies:

(show top 50) (show all 741)
id Title Authors Year
1
Production of Recombinant Rabies Virus Glycoprotein by Insect Cells in a Single-Use Fixed-Bed Bioreactor. ( 28921430 )
2018
2
Immunogenicity of ORFV-based vectors expressing the rabies virus glycoprotein in livestock species. ( 28898730 )
2017
3
High Incidence of Human Rabies Exposure in Northwestern Tigray, Ethiopia: A Four-Year Retrospective Study. ( 28060935 )
2017
4
Identification of two classes of somatosensory neurons that display resistance to retrograde infection by rabies virus. ( 28951448 )
2017
5
Life-Long Genetic and Functional Access to Neural Circuits Using Self-Inactivating Rabies Virus. ( 28689641 )
2017
6
Single visit rabies pre-exposure priming induces a robust anamnestic antibody response after simulated post-exposure vaccination: results of a dose-finding study. ( 28931127 )
2017
7
A novel approach to a rabies vaccine based on a recombinant single-cycle flavivirus vector. ( 28899628 )
2017
8
The Middle East and Eastern Europe rabies Expert Bureau (MEEREB) third meeting: Lyon-France (7-8 April, 2015). ( 28476258 )
2017
9
Editorial: Towards Elimination of Dog Mediated Human Rabies. ( 28913342 )
2017
10
Rabies Tracing of Birthdated Dentate Granule Cells in Rat Temporal Lobe Epilepsy. ( 28470680 )
2017
11
Comprehensive Monosynaptic Rabies Virus Mapping of Host Connectivity with Neural Progenitor Grafts after Spinal Cord Injury. ( 28479302 )
2017
12
Correction: Management and modeling approaches for controlling raccoon rabies: The road to elimination. ( 28463964 )
2017
13
Organization of dopamine and serotonin system: Anatomical and functional mapping of monosynaptic inputs using rabies virus. ( 28476484 )
2017
14
Expression of interleukin-6 by a recombinant rabies virus enhances its immunogenicity as a potential vaccine. ( 28089546 )
2017
15
Enhanced Immune Response to Rabies Viruses by the Use of a Liposome Adjuvant in Vaccines. ( 28953450 )
2017
16
A Pan-Lyssavirus Taqman Real-Time RT-PCR Assay for the Detection of Highly Variable Rabies virus and Other Lyssaviruses. ( 28081126 )
2017
17
Time to appreciate Avicenna's knowledge of rabies. ( 28503287 )
2017
18
Re-emergence of rabies virus maintained by canid populations in Paraguay. ( 28913904 )
2017
19
Development of molecular confirmation tools for swift and easy rabies diagnostics. ( 28938887 )
2017
20
Oral vaccination of wildlife using a vaccinia-rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG(Ar)): a global review. ( 28938920 )
2017
21
Substantial reductions in rabies, but still a lot to be done. ( 28911756 )
2017
22
Susceptibility of neuroblastoma cells to rabies virus may be affected by passage number. ( 28506631 )
2017
23
Human Rabies - Puerto Rico, 2015. ( 28056006 )
2017
24
A Self-Killing Rabies Virus That Leaves a Trace on the DNA. ( 28890212 )
2017
25
Phosphoprotein Gene Contributes to the Enhanced Apoptosis Induced by Wild-Type Rabies Virus GD-SH-01 In Vitro. ( 28928726 )
2017
26
Targeting the central nervous system (CNS): a review of rabies virus-targeting strategies. ( 28514853 )
2017
27
Assessing the Risk of a Canine Rabies Incursion in Northern Australia. ( 28913341 )
2017
28
Rabies surveillance in the United States during 2015. ( 28467751 )
2017
29
A novel in vitro ELISA for estimation of glycoprotein content in human rabies vaccines. ( 28436708 )
2017
30
Immunogenicity and Safety of Purified Vero Cell Rabies Vaccine (PVRV) under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above. ( 28045585 )
2017
31
Investigating the effect of carbon source on rabies virus glycoprotein production in Pichia pastoris by a transcriptomic approach. ( 28523730 )
2017
32
Rabies screen reveals GPe control of cocaine-triggered plasticity. ( 28902833 )
2017
33
Sero-prevalence of virus neutralizing antibodies for rabies in different groups of dogs following vaccination. ( 28521804 )
2017
34
Rabies Virus Infection Induces Microtubule Depolymerization to Facilitate Viral RNA Synthesis by Upregulating HDAC6. ( 28491824 )
2017
35
Monosynaptic Tracing in Developing Circuits Using Modified Rabies Virus. ( 27943201 )
2017
36
Fusion peptide improves stability and bioactivity of single chain antibody against rabies virus. ( 28068664 )
2017
37
Could the RTS,S/AS01 meningitis safety signal really be a protective effect of rabies vaccine? ( 28065475 )
2017
38
Resurgence of rabies in Hungary during 2013-2014: An attempt to track the origin of identified strains. ( 28497505 )
2017
39
The Ilocos Norte Communities against Rabies Exposure Elimination Project in the Philippines: Epidemiological and Economic Aspects. ( 28484703 )
2017
40
Type 1 Immune Mechanisms Driven by the Response to Infection with Attenuated Rabies Virus Result in Changes in the Immune Bias of the Tumor Microenvironment and Necrosis of Mouse GL261 Brain Tumors. ( 28461570 )
2017
41
Indigenous Wildlife Rabies in Taiwan: Ferret Badgers, a Long Term Terrestrial Reservoir. ( 28497055 )
2017
42
Multi-Patient Rabies Exposure on a Colorado River Rafting Expedition: Urgent vs. Emergent Transport Decision Making in an Austere Setting. ( 28952816 )
2017
43
Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA - Results of an international collaborative study. ( 28081969 )
2017
44
Inhibition of MEK-ERK1/2-MAP kinase signalling pathway reduces rabies virus induced pathologies in mouse model. ( 28939254 )
2017
45
Rescue of a wild-type rabies virus from cloned cDNA and assessment of the proliferative capacity of recombinant viruses. ( 28447192 )
2017
46
Risk assessment of the entry of canine-rabies into Papua New Guinea via sea and land routes. ( 28903875 )
2017
47
Rabies Vaccination Targets for Stray Dog Populations. ( 28451589 )
2017
48
Effect of counselling on health-care-seeking behaviours and rabies vaccination adherence after dog bites in Haiti, 2014-15: a retrospective follow-up survey. ( 28911750 )
2017
49
Serologic response in eight alpacas vaccinated by extralabel use of a large animal rabies vaccine during a public health response to a rabid alpaca in South Carolina. ( 27585106 )
2016
50
Correction: Human Rabies Survivors in India: An Emerging Paradox? ( 27557081 )
2016

Variations for Rabies

Expression for Rabies

Search GEO for disease gene expression data for Rabies.

Pathways for Rabies

Pathways related to Rabies according to GeneCards Suite gene sharing:

(show all 21)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 CCL5 CD40LG CXCL10 IFNA4 IKBKE IRF3
2
Show member pathways
13.26 CCL5 CD40LG CXCL10 IKBKE NGFR STAT1
3
Show member pathways
13.13 CCL5 CD40LG CXCL10 IFNA4 IRF3 MX1
4
Show member pathways
12.86 CCL5 IFNA4 IKBKE IRF3 STAT1 STAT2
5
Show member pathways
12.75 CCL5 CXCL10 IFNA4 IKBKE IRF3 STAT1
6
Show member pathways
12.6 CCL5 CXCL10 IFNA4 IKBKE IRF3
7 12.54 IFNA4 IKBKE IRF3 MX1 NGFR STAT1
8
Show member pathways
12.5 CD40LG IKBKE IRF3 NGFR TLR3
9
Show member pathways
12.48 CD40LG IKBKE PML STAT1
10
Show member pathways
12.29 IFNA4 IRF3 MX1 NCAM1 PML STAT1
11
Show member pathways
12.14 IKBKE IRF3 STAT1 TLR3
12 12.1 CCL5 CD40LG CXCL10 IKBKE IRF3 NCAM1
13
Show member pathways
12.06 IFNA4 IRF3 MX1 STAT1 STAT2
14
Show member pathways
12.01 CCL5 CXCL10 IFNA4 IKBKE IRF3 MX1
15 11.93 NCAM1 NGFR STAT1
16 11.89 ALB NCAM1 NGFR
17
Show member pathways
11.78 STAT1 STAT2 TLR3
18 11.78 IFNA4 IKBKE STAT1 STAT2
19 11.75 IFNA4 IKBKE IRF3 STAT1 STAT2 TLR3
20 11.27 CXCL10 STAT1 STAT2
21
Show member pathways
11.03 IRF3 MX1 STAT1 STAT2

GO Terms for Rabies

Cellular components related to Rabies according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 ALB CCL5 CD40LG CXCL10 IFNA4 NCAM1
2 cell surface GO:0009986 9.35 CD40LG IGHM NCAM1 NGFR TLR3
3 external side of plasma membrane GO:0009897 8.92 CD40LG CXCL10 IGHM NCAM1

Biological processes related to Rabies according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.97 CCL5 CD40LG CXCL10 IKBKE NGFR
2 viral process GO:0016032 9.89 IRF3 NCAM1 PML STAT1 STAT2
3 inflammatory response GO:0006954 9.88 CCL5 CD40LG CXCL10 NGFR TLR3
4 immune system process GO:0002376 9.85 IRF3 MX1 PML TLR3
5 tumor necrosis factor-mediated signaling pathway GO:0033209 9.8 CD40LG NGFR STAT1
6 innate immune response GO:0045087 9.8 IFNA4 IGHM IKBKE IRF3 MX1 PML
7 negative regulation of angiogenesis GO:0016525 9.76 CXCL10 PML STAT1
8 defense response GO:0006952 9.76 CXCL10 IFNA4 MX1 TLR3
9 response to cytokine GO:0034097 9.7 CCL5 PML STAT1
10 positive regulation of monocyte chemotaxis GO:0090026 9.62 CCL5 CXCL10
11 interferon-gamma-mediated signaling pathway GO:0060333 9.62 IRF3 NCAM1 PML STAT1
12 cellular response to interferon-beta GO:0035458 9.61 STAT1 TLR3
13 positive regulation of T cell migration GO:2000406 9.61 CCL5 CXCL10
14 response to exogenous dsRNA GO:0043330 9.61 IFNA4 IRF3 TLR3
15 I-kappaB phosphorylation GO:0007252 9.59 IKBKE TLR3
16 response to interferon-beta GO:0035456 9.58 IKBKE STAT1
17 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.58 IKBKE IRF3 TLR3
18 response to type I interferon GO:0034340 9.56 IKBKE MX1
19 response to virus GO:0009615 9.55 CCL5 CXCL10 IFNA4 MX1 TLR3
20 cellular response to dsRNA GO:0071359 9.54 IRF3 TLR3
21 regulation of type I interferon-mediated signaling pathway GO:0060338 9.54 IFNA4 STAT1 STAT2
22 cellular response to interferon-gamma GO:0071346 9.51 CCL5 TLR3
23 type I interferon signaling pathway GO:0060337 9.35 IFNA4 IRF3 MX1 STAT1 STAT2
24 positive regulation of interferon-alpha production GO:0032727 9.3 IRF3
25 defense response to virus GO:0051607 9.23 CXCL10 IFNA4 IRF3 MX1 PML STAT1
26 apoptotic process GO:0006915 10.02 IRF3 MX1 NGFR PML STAT1

Molecular functions related to Rabies according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.43 ALB IRF3 MX1 STAT1 STAT2 TLR3
2 cytokine activity GO:0005125 8.92 CCL5 CD40LG CXCL10 IFNA4
3 protein binding GO:0005515 10 ALB CCL5 CD40LG CXCL10 IFNA4 IGHM

Sources for Rabies

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....